Gene-Edited immune cells take on Hard-to-Treat blood cancers

NCT ID NCT06492304

First seen Apr 05, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This study tested a new treatment called CTX131 for adults with blood cancers (lymphoma or leukemia) that came back or didn't respond to standard therapy. CTX131 uses CRISPR gene editing to create donor immune cells that target a protein called CD70 on cancer cells. The goal was to check safety and see if the treatment shrinks tumors. Only 12 people took part, so results are very early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site 1

    Houston, Texas, 77030, United States

  • Research Site 2

    The Bronx, New York, 10467, United States

  • Research Site 3

    Boston, Massachusetts, 02114, United States

  • Research Site 4

    New York, New York, 10065, United States

  • Research Site 5

    Stanford, California, 94305, United States

  • Research Site 6

    Phoenix, Arizona, 85054, United States

  • Research Site 7

    East Melbourne, Victoria, 3002, Australia

Conditions

Explore the condition pages connected to this study.